

## Special Issue

# Vaccine Response in the Immunocompromised Patient with Focus on Cellular Immunity

### Message from the Guest Editor

The immunocompromised patient has an increased risk of any type of infectious disease, including vaccine-preventable diseases, and often suffers a severe course. Although inactivated vaccines can be safely administered even in severely immunocompromised patients, vaccine rates are particularly low in this vulnerable population. The tailoring of vaccine strategies to the needs of immunosuppressed patients relies on a better understanding of what supports or limits vaccine efficacy. In addition to antibody-mediated protection, cellular immunity is of particular importance, as T cell responses also participate in the reduction, control, and clearance of pathogens. Therefore, articles adding new information on vaccine-induced, cell-mediated immune response in immunocompromised patients are welcome. Adding new information on this subject may lead to a better understanding of the immune response to available vaccines or new vaccine candidates in these particularly vulnerable patients and might help in optimizing vaccine strategies in the future.

### Guest Editor

Dr. Christina Bahrs

1. Institute of Infectious Diseases and Infection Control, Jena University Hospital/Friedrich-Schiller-University, 07743 Jena, Germany
2. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, 1090 Vienna, Austria

### Deadline for manuscript submissions

closed (31 December 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/71318](https://mdpi.com/si/71318)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).